HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Phosphodiesterase inhibitors for pulmonary hypertension.

AuthorsEmmanuel Bergot, Romain Magnier, Gérard Zalcman
JournalThe New England journal of medicine (N Engl J Med) Vol. 362 Issue 6 Pg. 559; author reply 560 (Feb 11 2010) ISSN: 1533-4406 [Electronic] United States
PMID20147727 (Publication Type: Comment, Letter)
Chemical References
  • Phosphodiesterase 5 Inhibitors
  • Phosphodiesterase Inhibitors
  • Piperazines
  • Purines
  • Sulfones
  • Sildenafil Citrate
Topics
  • Humans
  • Hypertension, Pulmonary (drug therapy, etiology)
  • Phosphodiesterase 5 Inhibitors
  • Phosphodiesterase Inhibitors (adverse effects, therapeutic use)
  • Piperazines (therapeutic use)
  • Pulmonary Edema (chemically induced)
  • Pulmonary Veno-Occlusive Disease (complications, diagnosis, therapy)
  • Purines (therapeutic use)
  • Sildenafil Citrate
  • Sulfones (therapeutic use)
  • Ventricular Dysfunction, Left (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: